Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 9 - Losing the Life Lottery because of Where You Are Born

  • from Part Three - The Prevention Problem
  • Linda Eckert, University of Washington
  • Book:
    Enough
    Published online:
    11 January 2024
    Print publication:
    11 January 2024, pp 113-127

  • Summary

    While countries with soaring cervical cancer rates would dearly love to offer citizens the HPV vaccine, their governments struggle most to afford it. In the poorest parts of the world, shortages, dosage costs, and barriers to distribution and delivery have made HPV vaccine access like winning a “life lottery” – garnering them no more than 13 percent of the global share. Despite the efforts of nonprofit agencies like Gavi – a vaccine-funding provider for the world’s poorest countries – this potent source of prevention remains elusive for “caught-in-the-middle” nations deemed above the funding cut-off. No such shortage exists in the United States, which pays $160 USD a dose and recently expanded vaccine eligibility in females up to forty-five, despite peak efficacy in teen girls. Market forces perpetuate the battle for this precious resource, even though widespread screening and pre-cancer treatment won’t be enough to stop the disease. In the absence of widespread HPV vaccination, global cervical cancer elimination remains a distant hope.